WF
BMY.RT

Welch & Forbes’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Welch & Forbes’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,405
Closed -$39K – 354
2020
Q1 		$39K Buy
+10,405
New +$34.3K ﹤0.01% 328

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Welch & Forbes's BMY.RT Position: Q2 2020 in Review

Welch & Forbes sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q2 2020, closing a stake of 10,405 shares — an estimated $39K sold.

Welch & Forbes first reported a position in BMY.RT in Q1 2020 and held it in 1 quarter. The position peaked at $39K in Q1 2020. 583 funds tracked by Wall St. Rank hold BMY.RT as of Q2 2020.

  • Welch & Forbes reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q2 2020 after selling out during the quarter.
  • Welch & Forbes sold 10,405 Bristol-Myers Squibb Company Contingent Value Rights shares in Q2 2020, an estimated $39K.
  • Welch & Forbes first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 1 quarter.
  • Welch & Forbes's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $39K in Q1 2020.
  • 583 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q2 2020.

Based on Welch & Forbes's 13F filing for Q2 2020, filed 15 Jul 2020.